Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled HH-120 in Healthy Volunteers
NCT05116865Phase 1Completed
- Sponsor
- Huahui Health
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HH-120 in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by Huahui Health. Primary endpoints: Number of participants with treatment emergent adverse events, Severity of treatment emergent adverse events and 4 more. Started Nov 2021; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05116865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116865.